Eisler Capital Management Ltd. Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Eisler Capital Management Ltd. acquired a new stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 112,700 shares of the biotechnology company's stock, valued at approximately $846,000.

A number of other hedge funds have also recently modified their holdings of the stock. R Squared Ltd acquired a new position in shares of Grifols during the 4th quarter worth approximately $28,000. GAMMA Investing LLC lifted its holdings in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,527 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in Grifols in the 4th quarter worth about $75,000.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley assumed coverage on Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Price Performance

GRFS traded up $0.38 on Thursday, hitting $7.95. 1,048,968 shares of the company's stock were exchanged, compared to its average volume of 1,171,192. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The stock has a market cap of $5.46 billion, a price-to-earnings ratio of 6.79 and a beta of 0.44. The firm has a 50-day moving average price of $7.29 and a 200-day moving average price of $7.64. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.